Dr. Evgeny Kiner is the CEO & Founder of NeoSplice Therapeutics, an AI-driven platform company unlocking disease-specific therapeutic targets that are inaccessible to traditional genomics. He was trained in RNA biology at Massachusetts Institute of Technology under Phillip Sharp, and later in systems immunology at Harvard University with Diane Mathis and Christophe Benoist, where he helped bring single-cell RNA sequencing into large-scale immune profiling efforts as part of the Immgen consortium. Prior to NeoSplice, he was a founding scientist at Immunai, where he helped build AI-driven platforms for biological discovery.